DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
DENAGLIPTIN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
DENAGLIPTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DOS9ZOT21L
Molecule Type:
Small molecule
Molecular Formula:
C20H18F3N3O
Molecular Weight:
373.38
AlogP:
2.89
PSA:
70.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
LADOSTIGIL
2
Small molecule
Investigational
Unknown
Unknown
Dementia
Unknown
LADOSTIGIL
×
Maximum Phase:
2
First Approval:
None
UNII:
SW3H1USR4Q
Molecule Type:
Small molecule
Molecular Formula:
C16H20N2O2
Molecular Weight:
272.35
AlogP:
2.35
PSA:
41.57
HBD:
1.0
HBA:
#RotB:
4.0
Source:
EDRALBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Neuromyelitis Optica
Unknown
EDRALBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H21F2N5O3
Molecular Weight:
489.48
AlogP:
3.84
PSA:
106.24
HBD:
2.0
HBA:
#RotB:
4.0
Source:
FE 202767
2
Protein
Investigational
Unknown
Unknown
Premature Birth
Oxytocin receptor agonist
FE 202767
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BI-811283
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Leukemia, Myeloid, Acute
Serine/threonine-protein kinase Aurora-B inhibitor
BI-811283
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRX0014
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TRX0014
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SDX-101
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma
Retinoid X receptor alpha modulator
SDX-101
×
Maximum Phase:
2
First Approval:
None
UNII:
Y1RAH31T6K
Molecule Type:
Small molecule
Molecular Formula:
C17H21NO3
Molecular Weight:
287.36
AlogP:
3.38
PSA:
62.32
HBD:
2.0
HBA:
#RotB:
4.0
Source:
MSB0011359C
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
MSB0011359C
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
R-348
2
Small molecule
Investigational
Unknown
Unknown
Dry Eye Syndromes; Graft vs Host Disease
Tyrosine-protein kinase JAK3 inhibitor
R-348
×
Maximum Phase:
2
First Approval:
None
UNII:
3J396119JY
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCANTHONE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Glioblastoma
Unknown
LUCANTHONE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
918K9N56QZ
Molecule Type:
Small molecule
Molecular Formula:
C20H25ClN2OS
Molecular Weight:
376.95
AlogP:
4.48
PSA:
32.34
HBD:
1.0
HBA:
#RotB:
6.0
Source:
LJN452
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LJN452
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SERALUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary
Unknown
SERALUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C27H27N5O3
Molecular Weight:
469.55
AlogP:
5.29
PSA:
98.26
HBD:
2.0
HBA:
#RotB:
8.0
Source:
IBODUTANT
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Neurokinin 2 receptor antagonist
IBODUTANT
×
Maximum Phase:
2
First Approval:
None
UNII:
1H7RSQ28BJ
Molecule Type:
Small molecule
Molecular Formula:
C37H48N4O4S
Molecular Weight:
644.88
AlogP:
5.23
PSA:
99.77
HBD:
3.0
HBA:
#RotB:
11.0
Source:
DP001
2
Small molecule
Investigational
Unknown
Unknown
Osteoporosis, Postmenopausal; Hyperparathyroidism, Secondary; Osteoporosis
Vitamin D receptor agonist
DP001
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C27H44O3
Molecular Weight:
416.65
AlogP:
5.7
PSA:
60.69
HBD:
3.0
HBA:
#RotB:
6.0
Source:
NESVACUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Macular Degeneration
Angiopoietin-2 inhibitor
NESVACUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WX8293WGLC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOL101
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TOL101
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GAMMA TOCOPHEROL
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GAMMA TOCOPHEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMA0076
2
Small molecule
Investigational
Unknown
Unknown
Glaucoma; Ocular Hypertension
Rho-associated protein kinase inhibitor
AMA0076
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PYROPHOSPHORIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PYROPHOSPHORIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
4E862E7GRQ
Molecule Type:
Small molecule
Molecular Formula:
H4O7P2
Molecular Weight:
177.97
AlogP:
-0.81
PSA:
124.29
HBD:
4.0
HBA:
#RotB:
2.0
Source:
ANTIMONY
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis, Cutaneous
Unknown
ANTIMONY
×
Maximum Phase:
2
First Approval:
None
UNII:
9IT35J3UV3
Molecule Type:
Small molecule
Molecular Formula:
Sb
Molecular Weight:
121.76
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MITOQUINONE CATION
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MITOQUINONE CATION
×
Maximum Phase:
2
First Approval:
None
UNII:
47BYS17IY0
Molecule Type:
Small molecule
Molecular Formula:
C37H44O4P+
Molecular Weight:
583.73
AlogP:
7.46
PSA:
52.6
HBD:
0.0
HBA:
#RotB:
16.0
Source:
BMS-986253
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BMS-986253
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROBALZOTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 1a (5-HT1a) receptor antagonist
ROBALZOTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
I18M56OGME
Molecule Type:
Small molecule
Molecular Formula:
C18H23FN2O2
Molecular Weight:
318.39
AlogP:
2.64
PSA:
55.56
HBD:
1.0
HBA:
#RotB:
4.0
Source:
PX-102
2
Small molecule
Investigational
Unknown
Unknown
Non-alcoholic Fatty Liver Disease
Bile acid receptor FXR agonist
PX-102
×
Maximum Phase:
2
First Approval:
None
UNII:
378SU5NO8S
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-223131
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Calcium-activated potassium channel subunit alpha-1 activator
BMS-223131
×
Maximum Phase:
2
First Approval:
None
UNII:
889F719S7K
Molecule Type:
Small molecule
Molecular Formula:
C18H13ClF3NO3
Molecular Weight:
383.75
AlogP:
4.11
PSA:
73.32
HBD:
3.0
HBA:
#RotB:
3.0
Source:
ORVEPITANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Stress Disorders, Post-Traumatic
Neurokinin 1 receptor antagonist
ORVEPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
IIU6V0W3JD
Molecule Type:
Small molecule
Molecular Formula:
C31H35F7N4O2
Molecular Weight:
628.63
AlogP:
6.8
PSA:
47.1
HBD:
0.0
HBA:
#RotB:
4.0
Source:
D-ASPARTATE
2
Small molecule
Investigational
Unknown
Unknown
Brain Injuries; Multiple Sclerosis, Relapsing-Remitting
Unknown
D-ASPARTATE
×
Maximum Phase:
2
First Approval:
None
UNII:
4SR0Q8YD1X
Molecule Type:
Small molecule
Molecular Formula:
C4H7NO4
Molecular Weight:
133.1
AlogP:
-1.13
PSA:
100.62
HBD:
3.0
HBA:
#RotB:
3.0
Source:
BORAGE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
BORAGE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AB122
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AB122
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BAFETINIB
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Prostatic Neoplasms, Castration-Resistant
Tyrosine-protein kinase ABL inhibitor
BAFETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
NVW4Z03I9B
Molecule Type:
Small molecule
Molecular Formula:
C30H31F3N8O
Molecular Weight:
576.63
AlogP:
5.39
PSA:
99.17
HBD:
2.0
HBA:
#RotB:
8.0
Source:
THK-5351
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
THK-5351
×
Maximum Phase:
2
First Approval:
None
UNII:
JE3F6WUN31
Molecule Type:
Small molecule
Molecular Formula:
C18H18FN3O2
Molecular Weight:
327.36
AlogP:
3.05
PSA:
67.27
HBD:
2.0
HBA:
#RotB:
6.0
Source:
DOLASTATIN-10
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Gallbladder Neoplasms; Kidney Neoplasms; Leukemia; Lymphoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma
Tubulin inhibitor
DOLASTATIN-10
×
Maximum Phase:
2
First Approval:
None
UNII:
EI946JT51X
Molecule Type:
Small molecule
Molecular Formula:
C42H68N6O6S
Molecular Weight:
785.11
AlogP:
5.19
PSA:
133.41
HBD:
2.0
HBA:
#RotB:
21.0
Source:
TRETAZICAR
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular
Unknown
TRETAZICAR
×
Maximum Phase:
2
First Approval:
None
UNII:
7865D5D01M
Molecule Type:
Small molecule
Molecular Formula:
C9H8N4O5
Molecular Weight:
252.19
AlogP:
0.42
PSA:
132.38
HBD:
1.0
HBA:
#RotB:
4.0
Source:
CE-224535
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Osteoarthritis
P2X purinoceptor 7 antagonist
CE-224535
×
Maximum Phase:
2
First Approval:
None
UNII:
T8B02RAU3C
Molecule Type:
Small molecule
Molecular Formula:
C22H29ClN4O6
Molecular Weight:
480.95
AlogP:
0.87
PSA:
135.68
HBD:
3.0
HBA:
#RotB:
8.0
Source:
BEPIROVIRSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Hepatitis B, Chronic
mRNA antisense inhibitor
BEPIROVIRSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
170
171
172
173
174
175
176
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA